| LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma (NCT03773107) | Wake Forest University Health Sciences | 2019-01-03 |
| Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma (NCT03669445) | University Hospital, Toulouse | 2018-12-31 |
| Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (NCT03710603) | Stichting European Myeloma Network | 2018-12-14 |
| An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (NCT03601078) | Celgene | 2018-12-13 |
| Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (NCT03697655) | Polish Myeloma Consortium | 2018-12-10 |
| A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma (NCT03767751) | Chinese PLA General Hospital | 2018-12-05 |
| A Study of Colesevelam for Lenalidomide-Associated Diarrhea (NCT03767257) | Memorial Sloan Kettering Cancer Center | 2018-12-03 |
| An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma (NCT03227432) | Dana-Farber Cancer Institute | 2018-12-01 |
| Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma (NCT03983486) | Centre Hospitalier Universitaire, Amiens | 2018-11-30 |
| 64Cu-LLP2A for Imaging Multiple Myeloma (NCT03804424) | Washington University School of Medicine | 2018-11-20 |
| CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig (NCT03383055) | Masonic Cancer Center, University of Minnesota | 2018-11-16 |
| VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma (NCT04151615) | Boryung Pharmaceutical Co., Ltd | 2018-11-15 |
| A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (NCT03652064) | Janssen Research & Development, LLC | 2018-11-06 |
| A Safety Study of SEA-BCMA in Patients With Multiple Myeloma (NCT03582033) | Seagen Inc. | 2018-11-01 |
| Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 (NCT03741127) | Poseida Therapeutics, Inc. | 2018-10-29 |
| Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (NCT03634800) | Weill Medical College of Cornell University | 2018-10-23 |
| Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma (NCT03733717) | Sanofi | 2018-10-22 |
| A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. (NCT03539744) | AbbVie | 2018-10-22 |
| Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (NCT03617731) | University of Heidelberg Medical Center | 2018-10-18 |
| Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor (NCT04650724) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-10-11 |
| Quality of Life in Patients With Multiple Myeloma-validation Study (NCT03537222) | Zurich University of Applied Sciences | 2018-10-10 |
| Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide (NCT03411031) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-04 |
| Safety and Efficacy Assessments of Osalmid in Multiple Myeloma (NCT03670173) | Shanghai 10th People's Hospital | 2018-10-01 |
| To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT03544281) | GlaxoSmithKline | 2018-09-20 |
| Chemotherapy and G-CSF for Mobilization (NCT03442673) | Insel Gruppe AG, University Hospital Bern | 2018-09-17 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |
| NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (NCT03399448) | University of Pennsylvania | 2018-09-05 |
| A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion (NCT03570983) | Swedish Medical Center | 2018-09-05 |
| BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma (NCT04156269) | iCell Gene Therapeutics | 2018-08-31 |
| PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function (NCT03639610) | Oncopeptides AB | 2018-08-28 |
| Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography (NCT03779815) | Ulsan University Hospital | 2018-08-20 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| Determining Normal Range for Free Light Chains in Serum Among Twins (NCT04191057) | University of California, San Francisco | 2018-08-15 |
| Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis (NCT03506386) | Takeda | 2018-08-09 |
| Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells (NCT03628612) | Autolus Limited | 2018-08-02 |
| AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities (NCT07410403) | Fuling Zhou | 2018-08-01 |
| Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM (NCT03605056) | Peng Liu | 2018-07-31 |
| CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma (NCT03672253) | Second Affiliated Hospital of Xi'an Jiaotong University | 2018-07-26 |
| A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain (NCT03602755) | Celgene | 2018-07-19 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235) | Noah Merin | 2018-07-18 |
| "FU-IFM2009" Database Post IFM/DFCI 2009 Study (NCT03679351) | University Hospital, Toulouse | 2018-07-15 |
| Symbenda Post-Marketing Surveillance (PMS) (NCT02434484) | Eisai Korea Inc. | 2018-07-04 |
| A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation (NCT03556332) | Memorial Sloan Kettering Cancer Center | 2018-07-02 |
| Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma (NCT03848676) | University of Turin, Italy | 2018-07-01 |
| Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (NCT03619252) | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 2018-07-01 |
| Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM (NCT04500431) | Shanghai Tongji Hospital, Tongji University School of Medicine | 2018-07-01 |
| A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (NCT03548207) | Janssen Research & Development, LLC | 2018-06-29 |
| A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (NCT03525678) | GlaxoSmithKline | 2018-06-18 |
| Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone (NCT03375567) | Yale University | 2018-06-04 |
| Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients (NCT03376672) | Raija Silvennoinen | 2018-05-31 |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (NCT03530683) | Pfizer | 2018-05-14 |
| Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma (NCT03549442) | University of Pennsylvania | 2018-05-09 |
| Short Course Daratumumab in Patients With Multiple Myeloma (NCT03490344) | Memorial Sloan Kettering Cancer Center | 2018-05-03 |
| A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens (NCT03412565) | Janssen Research & Development, LLC | 2018-04-26 |
| A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) (NCT03439280) | Millennium Pharmaceuticals, Inc. | 2018-04-20 |
| Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM (NCT03481556) | Oncopeptides AB | 2018-04-12 |
| High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment (NCT03234335) | Centre Hospitalier Universitaire de Saint Etienne | 2018-04-10 |
| Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma (NCT03493737) | Central Hospital, Nancy, France | 2018-04-10 |
| Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma (NCT03486067) | Celgene | 2018-04-03 |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma (NCT03314181) | AbbVie | 2018-04-02 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation (NCT03508765) | Memorial Sloan Kettering Cancer Center | 2018-03-27 |
| A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) (NCT03246529) | BioLineRx, Ltd. | 2018-03-23 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606) | Canadian Cancer Trials Group | 2018-03-23 |
| Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma (NCT03700450) | Universitätsklinikum Hamburg-Eppendorf | 2018-03-16 |
| A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) (NCT03439293) | Takeda | 2018-03-13 |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma (NCT03448978) | Cartesian Therapeutics | 2018-03-08 |
| ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (NCT03441958) | Ciusss de L'Est de l'Île de Montréal | 2018-03-07 |
| The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients (NCT04303091) | Dr. Nicole Culos-Reed | 2018-03-02 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma (NCT02958969) | Gregory Piazza | 2018-02-28 |
| PRospective Multiple Myeloma Impact Study (NCT02911571) | SkylineDx | 2018-02-27 |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03266692) | Cogent Biosciences, Inc. | 2018-02-22 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603) | Sutro Biopharma, Inc. | 2018-02-22 |
| Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma (NCT03201250) | University of Nebraska | 2018-02-21 |
| Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma (NCT03475628) | Hellenic Society of Hematology | 2018-02-21 |
| A Safety Study of SGN-CD48A in Patients With Multiple Myeloma (NCT03379584) | Seagen Inc. | 2018-02-20 |
| Multiple Myeloma Molecular Monitoring Study (NCT03421132) | Horizon Health Network | 2018-02-20 |
| Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft (NCT03393273) | Assistance Publique - Hôpitaux de Paris | 2018-02-20 |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-19 |
| Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant (NCT03413800) | Ciusss de L'Est de l'Île de Montréal | 2018-02-12 |
| Registry for Adults With Plasma Cell Disorders (PCD's) (NCT03717844) | UNC Lineberger Comprehensive Cancer Center | 2018-02-09 |
| A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (NCT03374085) | Celgene | 2018-02-06 |
| Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (NCT03430011) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-01 |
| LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma (NCT03361306) | Wake Forest University Health Sciences | 2018-01-09 |
| a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients (NCT04008888) | Institute of Hematology & Blood Diseases Hospital, China | 2018-01-05 |
| Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT (NCT03385096) | Nanfang Hospital, Southern Medical University | 2018-01-02 |
| Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma (NCT02976493) | Bristol-Myers Squibb | 2018-01-01 |
| Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea (NCT03288974) | Celgene | 2017-12-28 |
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma (NCT03111992) | Novartis Pharmaceuticals | 2017-12-18 |
| Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma (NCT03336073) | PETHEMA Foundation | 2017-12-18 |
| A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma (NCT03288480) | Promontory Therapeutics Inc. | 2017-12-15 |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis (NCT03315026) | Memorial Sloan Kettering Cancer Center | 2017-12-14 |
| Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (NCT03361748) | Celgene | 2017-12-13 |
| Study of BCMA CAR-T in Multiple Myeloma (NCT03322735) | Henan Cancer Hospital | 2017-12-08 |
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation (NCT03159702) | Medical College of Wisconsin | 2017-12-08 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (NCT03234972) | Janssen Research & Development, LLC | 2017-11-30 |
| PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma (NCT03269136) | Pfizer | 2017-11-29 |
| The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma (NCT03777306) | University of Alabama at Birmingham | 2017-11-27 |